Company intelligence / Profile preview

PureIMS

Ownership: Private
Development stage: Commercial

Overview

PureIMS has one product (Colistin Cyclops™) already marketed and reimbursed under a named patient program for cystic fibrosis treatment. Their lead candidate, Levodopa Cyclops™, is in final development stage as rescue therapy for OFF-episodes in Parkinson's disease. A Phase 1 clinical trial with Amikacin Cyclops® in TB patients was recently completed.

Therapeutic areas: PulmonologyImmunologyNeurologyInfectious Diseases
Modalities: Dry powder inhalation
Industry: Biotech

Drug pipeline

1 asset

Tobramycin Cyclops®

Preclinical

Partnerships

Seeking pharma/biotech partners for Cyclops™-based inhalation applications

Beyond the preview

Go deeper on PureIMS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PureIMS.

Explore the full profile